VCXB · 10x Capital Venture Acquisition Corp. III - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - |
| SG&A | $2.53M | $2.12M | $1.29M | - | $223.8K | $248.1K | $393.8K |
| Total Operating Expenses | - | - | - | - | - | - | - |
| D&A | - | - | - | - | - | - | - |
| Operating Income | ($2.65M) | ($2.23M) | ($1.40M) | - | ($336.3K) | ($386) | ($506.3K) |
| Interest Expense | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - |
| Net Income | ($2.29M) | ($1.78M) | $2.78M | - | ($12.8K) | ($386) | ($347.4K) |
| EPS - Basic | - | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $646.8K | $1.96M | $25.4K | $67.1K | $127.9K | $491.3K | $0 |
| Accounts Receivable | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - |
| Accounts Payable | $822.7K | $548.9K | $557.3K | $676.3K | $223.5K | $228.0K | $103.6K |
| Current Assets | $824.8K | $2.07M | $3.07M | $193.3K | $228.4K | $612.1K | $891.7K |
| Total Assets | $44.00M | $44.69M | $45.21M | $308.85M | $306.58M | $305.52M | $566.9K |
| Current Liabilities | $5.52M | $4.15M | $2.89M | $2.61M | $381.7K | $429.1K | $348.2K |
| Long-term Debt | - | - | - | - | - | - | - |
| Total Liabilities | $19.80M | $18.43M | $17.17M | $16.89M | $14.66M | $14.71M | $586.5K |
| Stockholders' Equity | ($18.88M) | ($16.27M) | ($14.00M) | ($16.59M) | $1.3K | $14.1K | $0 |
| Retained Earnings | ($18.88M) | ($16.27M) | ($14.00M) | ($16.59M) | ($14.33M) | ($14.00M) | ($44.6K) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | $208.3K | - | - | - | ($506.6K) |
| Investing Cash Flow | - | - | $266.70M | - | - | - | ($304.50M) |
| Financing Cash Flow | - | - | ($266.95M) | - | - | - | $305.68M |
| CapEx | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|
| Profitability | |||||||
| Gross margin | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - |
| Return on assets | -5.2% | -4.0% | 6.1% | - | -0.0% | -0.0% | -61.3% |
| Return on equity | 12.1% | 11.0% | -19.8% | - | -996.4% | -2.7% | - |
| Return on invested capital | - | - | - | - | - | - | - |
| Liquidity | |||||||
| Current ratio | 0.15 | 0.50 | 1.06 | 0.07 | 0.60 | 1.43 | 2.56 |
| Quick ratio | 0.15 | 0.50 | 1.06 | 0.07 | 0.60 | 1.43 | 2.56 |
| Cash ratio | 0.12 | 0.47 | 0.01 | 0.03 | 0.33 | 1.14 | 0.00 |
| Leverage | |||||||
| Debt / Equity | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - |
| Equity multiplier | -2.33 | -2.75 | -3.23 | -18.61 | 238958.29 | 21718.84 | - |
| Liabilities / Assets | 0.45 | 0.41 | 0.38 | 0.05 | 0.05 | 0.05 | 1.03 |
| Efficiency | |||||||
| Asset turnover | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - |
| Valuation | |||||||
| P / E | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| Growth | |||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -687.1% | -578868.1% | -177.3% | - | - | - | - |
| Net income growth (YoY) | -17821.3% | -461668.7% | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | - | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing 10X Capital Venture Acquisition Corp. III against the 5 most active filers in the same SIC group.